Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Good News
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(56)
•••
Comment by RalphRalphon Dec 30, 2020 10:40am
165 Views
Post# 32196800

RE:RE:Good News

RE:RE:Good NewsIf you're talking about an upfront payment on a licensing deal, I don't think there's much chance they get anything close to $300 million upfront payment.  I'd expect something closer to $30 - $40 million.

Given the volume of sales 346 could do, I'd rather they push for a larger royalty rate if they have to prioritize one of the two.  I would hope ideally for a royalty rate around 20% with production cost covered. 



Doccole wrote: With biopharm and deals-
say we make a licensing partnership deal with LATAM and it ups our cash position to 350m at 10%.  What would our stock most likely trade at? I imagine it would be much higher than a market cap of 350m.

i was looking online for examples, but I didn't know the way biopharm stocks are evaluated once a deal/cash infusion is established.  Dan said right now we should be at 400-600m, due to entering phase 3.  Thoughts?


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities